NAT2 and metabolic syndrome: Moreover, the risk alleles for dyslipidemia (e.g., rs1495741-G) are associated with rapid NAT2 acetylator phenotype, suggesting that increased systemic NAT2 activity contributes to increases in plasma lipid and cholesterol levels.